Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04576156 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
A Phase 3 study of Myelofibrosis, sponsored by Geron Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 327
- Enrollment target
- 20
- Study locations
NCT04576156 is a Phase 3 study of Myelofibrosis that is active but no longer recruiting, run by Geron Corporation. The registered enrollment target is 327 participants, above the 191-participant average among 61 other Myelofibrosis trials with a reported enrollment target (71% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT04576156, a Phase 3 study of Myelofibrosis, is active but no longer recruiting, sponsored by Geron Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 327 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
Conditions Studied
Interventions
- DRUG Imetelstat
- DRUG Best Available Therapy (BAT)
Study Locations (20)
California
- University of California-San Diego/Moores UCSD Cancer Center - La Jolla
- UCLA David Geffen School of Medicine - Los Angeles
Florida
- BRCR Medical Center Inc - Plantation
- University of South Florida - Tampa
Texas
- Oncology Consultants - Houston
- The University of Texas MD - Houston
Utah
- Community Cancer Trials of Utah - Ogden
- Utah Cancer Specialists - Salt Lake City
Connecticut
- Smilow Cancer Center at YNHH - New Haven
Kentucky
- Norton Cancer Institute - Louisville
Louisiana
- Ochsner Clinic Foundation - New Orleans
Maryland
- Maryland Oncology Hematology - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04576156
The ClinicalTrials.gov registry entry for NCT04576156 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 61 other Myelofibrosis trials with a reported enrollment target (71% higher). The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Imetelstat is the first listed.
NCT04576156 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04576156 about?
NCT04576156 is a clinical study titled "A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment". The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
What is the current status of trial NCT04576156?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 327 participants. The study started on 2021-04-12. Estimated completion is 2028-06-30.
What conditions does trial NCT04576156 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT04576156?
The interventions under investigation include: Imetelstat (DRUG), Best Available Therapy (BAT) (DRUG).
Who is sponsoring clinical trial NCT04576156?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04576156 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RECRUITING · Phase 3
-
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.